Advertisement

Topics

Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients

08:01 EDT 23 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Preclinical Data Demonstrate Synergistic Activity of SY-1425 with Standard-of-Care AML and MDS Therapies and Anti-CD38 Therapies, Strengthening Rationale for Ongoing and Future Clinical Investigation of SY-1425 as Both a Monothe...

Other Sources for this Article

Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

NEXT ARTICLE

More From BioPortfolio on "Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...